MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.clml.2023.03.010

Медицинская библиотека · Clinical lymphoma, myeloma & leukemia · 2023

Treatment Discontinuation Patterns for Patients With Chronic Lymphocytic Leukemia in Real-World Settings: Results From a Multi-Center International Study.

Shadman Mazyar, Manzoor Beenish S, Sail Kavita, Tuncer Hande H, Allan John N, Ujjani Chaitra, Emechebe Nnadozie, Kamalakar Rajesh, Coombs Catherine C, Leslie Lori, Barr Paul M, Brown Jennifer R, Eyre Toby A, Rampotas Alexandros, Schuh Anna, Lamanna Nicole, Skarbnik Alan, Roeker Lindsey E, Bannerji Rajat, Eichhorst Barbara, Fleury Isabelle, Davids Matthew S, Alhasani Hasan, Jiang Dingfeng, Hill Brian T, Schuster Stephen J, Brander Danielle M, Pivneva Irina, Burne Rebecca, Guerin Annie, Mato Anthony R

Многоцентровое исследованиеСтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

INTRODUCTION

This study assessed treatment discontinuation patterns and reasons among chronic lymphocytic leukemia (CLL) patients initiating first-line (1L) and second-line (2L) treatments in real-world settings.

MATERIALS AND

METHODS

Using deidentified electronic medical records from the CLL Collaborative Study of Real-World Evidence, premature treatment discontinuation was assessed among FCR, BR, BTKi-based, and BCL-2-based regimen cohorts.

RESULTS

Of 1364 1L patients (initiated in 1997-2021), 190/13.9% received FCR (23.7% discontinued prematurely); 255/18.7% received BR (34.5% discontinued prematurely); 473/34.7% received BTKi-based regimens, of whom 28.1% discontinued prematurely; and 43/3.2% received venetoclax-based regimens, of whom 16.3% discontinued prematurely (venetoclax monotherapy: 7/0.5%, of whom 42.9% discontinued; VG/VR: 36/2.6%, of whom 11.1% discontinued). The most common reasons for treatment discontinuation were adverse events (FCR: 25/13.2%; BR: 36/14.1%; BTKi-based regimens: 75/15.9%) and disease progression (venetoclax-based: 3/7.0%). Of 626 2L patients, 20/3.2% received FCR (50.0% discontinued); 62/9.9% received BR (35.5% discontinued); 303/48.4% received BTKi-based regimens, of whom 38.0% discontinued; and 73/11.7% received venetoclax-based regimens, of whom 30.1% discontinued (venetoclax monotherapy: 27/4.3%, of whom 29.6% discontinued; VG/VR: 43/6.9%, of whom 27.9% discontinued). The most common reasons for treatment discontinuation were adverse events (FCR: 6/30.0%; BR: 11/17.7%; BTKi-based regimens: 60/19.8%; venetoclax-based: 6/8.2%).

CONCLUSION

The findings of this study highlight the continued need for tolerable therapies in CLL, with finite therapy offering a better tolerated option for patients who are newly diagnosed or relapsed/refractory to prior treatments.

Для цитирования: Shadman Mazyar, Manzoor Beenish S, Sail Kavita, Tuncer Hande H, Allan John N, Ujjani Chaitra, Emechebe Nnadozie, Kamalakar Rajesh, Coombs Catherine C, Leslie Lori, Barr Paul M, Brown Jennifer R, Eyre Toby A, Rampotas Alexandros, Schuh Anna, Lamanna Nicole, Skarbnik Alan, Roeker Lindsey E, Bannerji Rajat, Eichhorst Barbara, Fleury Isabelle, Davids Matthew S, Alhasani Hasan, Jiang Dingfeng, Hill Brian T, Schuster Stephen J, Brander Danielle M, Pivneva Irina, Burne Rebecca, Guerin Annie, Mato Anthony R. Treatment Discontinuation Patterns for Patients With Chronic Lymphocytic Leukemia in Real-World Settings: Results From a Multi-Center International Study.. Clinical lymphoma, myeloma & leukemia. 2023. DOI: 10.1016/j.clml.2023.03.010.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.